Prediction of Coronary Heart Disease Events in Blood or Marrow Transplantation Recipients

Gangaraju, Radhika; Chen, Yanjun; Hageman, Lindsey; Landier, Wendy; Balas, Nora; Ross, Elizabeth; Francisco, Liton; Bosworth, Alysia; Te, Hok Sreng; Wong, F. Lennie; Weisdorf, Daniel J.; Bhatia, Ravi; Forman, Stephen J.; Armenian, Saro H.; Bhatia, Smita

doi:10.1016/j.jaccao.2023.03.013

Cited by 6 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The acute and long-term CV toxicities following hematopoietic stem cell transplantation (HSCT) are increasingly recognized as an important factor in the prognosis of stem cell recipients. 29,94 The acute CV toxicities of HSCT range from arrhythmias like AF to hypo-and hypertension to VTE. Acute GVHD is associated with thrombosis and inflammatory myocardial damage (myocarditis, HF, conduction abnormalities, arrhythmias, and pericardial effusions).…”

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

“…The risk for the development of CAD scales with the presence and control of CV risk factors at the time of HSCT, as well as radiation exposure. 94,95 High baseline CV risk characteristics for stem cell transplantation are allogenic HSCT, pre-existing CVD, multiple CV risk factors, cancer treatment history (mediastinal or mantle field radiation, alkylating agents, >250 mg/m 2 doxorubicin or equivalent), conditioning schemes including total body irradiation and/or alkylating agents and GVHD. If some or all of these factors are present, the patient should be considered to be at high risk of acute and long-term CV toxicities secondary to HSCT.…”

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

Spannbauer,

Bergler-Klein

2024

Hamostaseologie

View full text Add to dashboard Cite

Cardio-oncology, a burgeoning subspecialty, addresses the complex interplay between cardiology and oncology, particularly in light of increased cardiovascular (CV) disease mortality in cancer patients. This review provides a comprehensive overview of cardio-oncology with a focus on the therapies used in hematological malignancies. We explore the bidirectional relationship between heart failure and cancer, emphasizing the need for collaborative care. The review discusses risk stratification, highlighting the importance of baseline CV risk assessment and personalized surveillance regimens. Primary and secondary prevention strategies, including pharmacological interventions, are outlined. The review also delves into the cardiotoxicity associated with hematological cancer therapies, focusing on anthracyclines, Bruton kinase inhibitors, BCR-ABL tyrosine kinase inhibitors, CAR-T cell therapy, immune checkpoint inhibitors, multiple myeloma treatments, and hematopoietic stem cell transplantation. We then highlight the high risk of venous and arterial thromboembolisms in cancer patients and the challenges of anticoagulation management in cardio-oncology. Finally, the review touches on the importance of long-term follow-up and appropriate screening in cancer survivors at high risk of CV morbidity and mortality, based on their CV risk profile and the type and dose of cardiotoxic therapies they received such as anthracyclines or high radiation doses.

show abstract

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 99%

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

Spannbauer,

Bergler-Klein

2024

Hamostaseologie

View full text Add to dashboard Cite

show abstract

“… 5 , 6 Although cardiovascular disease after HCT includes coronary heart disease (CHD), cardiomyopathy, heart failure, stroke, and peripheral vascular disease, most of the previous studies combined all these events for analysis because of the limited number of events. In this issue of JACC: CardioOncology , Gangaraju et al 7 specifically focused on CHD after HCT using a large study population of the BMTSS (Bone Marrow Transplant Survivor Study). The study cohort included 6,677 patients who survived 2 years after HCT, and 249 CHD events were observed with a long median follow-up time of 9.2 years among survivors.…”

mentioning

confidence: 99%

Calculate Your Risk of Heart Attack After Hematopoietic Cell Transplantation

Inamoto

2023

JACC: CardioOncology

View full text Add to dashboard Cite

Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation

Hundal,

Curley,

Hamilton

2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion StatementCardiac dysfunction is a serious adverse effect of cancer therapies that can interfere with quality of life and impact long-term survival in patients with cancer. Hematopoietic cell transplantation is a potentially curative therapy for many advanced hematologic malignancies and bone marrow failure syndromes, however is associated with several short- and long-term adverse effects, including importantly, cardiovascular toxicities. The goal of this review article is to describe the cardiovascular events that may develop before, during, and after hematopoietic cell transplantation, review risk factors for short- and long-term cardiovascular toxicities, discuss approaches to cardiovascular risk stratification and evaluation, and highlight the research gaps in the consideration of cardiovascular disease in patients undergoing hematopoietic cell transplantation. Further understanding of cardiovascular events and the factors associated with cardiovascular disease will hopefully lead to novel interventions in managing and mitigating the significant long-term burden of late cardiovascular effects in transplant survivors.

show abstract

Prediction of Coronary Heart Disease Events in Blood or Marrow Transplantation Recipients

Cited by 6 publications

References 37 publications

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology

Calculate Your Risk of Heart Attack After Hematopoietic Cell Transplantation

Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation

Contact Info

Product

Resources

About